All In Biotech

Drug Trial Radar · NCT07388602

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone Versus Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of SCTC21C plus cyclophosphamide, bortezomib and dexamethasone (VCd) compared with VCd alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Conditions

  • Amyloidosis

Interventions

  • SCTC21CDrug

    Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous

  • BortezomibDrug

    Pharmaceutical form: Lyophilized powder for injection; Route of administration: Subcutaneous

  • DexamethasoneDrug

    Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous

  • CyclophosphamideDrug

    Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Overall Complete Hematologic Response (CHR)Time frame: Up to approximately 50 months after the First Participant In (FPI)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.